Monday, April 15, 2019

Contract drug manufacturer Catalent Inc. agreed to buy closely held Paragon Bioservices Inc. for $1.2 billion, according to people familiar with the matter, the latest deal in the emerging market for gene-therapy drugs.


from MarketWatch.com - Top Stories https://on.mktw.net/2P9SHFf

Related Posts:

  • LATEST STOCK MARKET NEWSIf you were waiting for cheaper Chinese smartphones to enter the U.S. market, you could have a long wait. from MarketWatch.com - Top Stories https://on.mktw.net/2LVw3m0 … Read More
  • LATEST STOCK MARKET NEWSThe right ways and wrong ways to share your cash with your kin. from MarketWatch.com - Top Stories https://on.mktw.net/2EvVwwn … Read More
  • LATEST STOCK MARKET NEWSFederal Reserve Chairman Jerome Powell on Monday evening made the case that business borrowing doesn’t represent the threat to the U.S. economy that subprime mortgages did a decade ago. from MarketWatch.com - Top Storie… Read More
  • LATEST STOCK MARKET NEWS News Category Alert Markets What You Need To Know Equity Corporate Actions Alert #2019-094 The Nasdaq Stock Market from NASDAQTrader.com http://bit.ly/2VPJsAw … Read More
  • LATEST STOCK MARKET NEWSIt’s really about abundance, says Jared Dillian. from MarketWatch.com - Top Stories https://on.mktw.net/2YBMcOT … Read More

0 comments:

Post a Comment

Followers

Contact Form

Name

Email *

Message *

Popular Posts

FOLLOW BY EMAIL

Enter your email address:

Delivered by FeedBurner